Ondine to Present at The Needham & Company Biotechnology and Medical Technology Conference



    VANCOUVER, June 13 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP) a medical technology company focused on photodisinfection technology,
today announced that its Chief Technology Officer, Dr. Nicolas Loebel, is
scheduled to present an overview of the Company's operations including a
discussion on its Periowave photodisinfection system at the Needham & Company,
LLC Sixth Annual Biotechnology and Medical Technology Conference. The
presentation is scheduled for 2:30 PM Eastern Time on Thursday June 14, 2007
at the New York Palace Hotel in New York City.
    Interested parties may access the live webcast by visiting the Company's
website at www.ondinebiopharma.com. Please connect at least 15 minutes prior
to the presentation to ensure adequate time for any software download that may
be required to join the webcast. An audio and slide archive of the
presentation will be available for approximately 90 days.

    About Periowave(TM) and Photodisinfection

    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
compounds to specifically target and destroy microbial pathogens and reduce
the symptoms of disease. The compounds are generally topically applied and one
or more lasers are used to activate the compounds and complete the
disinfection. The Photodisinfection technologies were developed by Professor
Michael Wilson and colleagues at the Eastman Dental Institute, University
College London, and licensed to Ondine by UCL Business PLC, University College
London. Additional information about Periowave(TM) is available at
www.periowave.com.

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading-edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance.
    The Company is headquartered in Vancouver, British Columbia, Canada, with
a research laboratory in Bothell, Washington, USA, and an international office
in St. Michael, Barbados. For additional information, please visit the
Company's website at: www.ondinebiopharma.com.

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release





For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890